Aug 7 |
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
|
Aug 2 |
VBI Vaccines provides restructuring proceedings update
|
Aug 2 |
VBI Vaccines Provides an Update on its Restructuring Proceedings
|
Jul 30 |
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
|
Jun 25 |
VBI Vaccines Announces Results of Annual General Meeting
|
May 29 |
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
|
May 22 |
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
|
May 15 |
VBI Vaccines GAAP EPS of -$0.73 misses by $0.20, revenue of $1.21M misses by $1.64M
|
May 15 |
VBI Vaccines Reports First Quarter 2024 Financial Results
|
Apr 16 |
VBI Vaccines FY Non-GAAP EPS of $3.96
|